BioWorld

Nov. 15, 2007

Nastech Trims Workforce, Spins Off Research In RNAi

A week after losing a major partnership, Nastech Pharmaceutical Co. Inc. said it plans to lay off up to 75 workers in an attempt to cut costs. (BioWorld Today) Read More

Merck Serono Takes Japanese Option To R763 From Rigel

It's Real This Time: Primate ESCs Created In Laboratory

Implicit Bioscience Resurrects Drug, Gets Biodefense Award

Other News To Note

Microbix Placement Gets $7M For Manufacturing Operations

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...